Background/Objectives: Sarcopenia is a condition marked by a continuous decline in skeletal muscle strength and volume, often leading to significant health complications. According to several articles, sarcopenia is highly prevalent in chronic pancreatitis (CP) due to exocrine pancreatic insufficiency. The aim of this meta-analysis was to determine the pooled prevalence and risk of sarcopenia among CP patients. Methods: The search process adhered to the PRISMA 2020 guidelines and was registered in PROSPERO under the identification number CRD42025637059. The search was conducted in the following databases: MEDLINE/PubMed, EMBASE, Cochrane, Google Scholar, and the Russian Science Citation Index (RSCI). It covered studies published between 1 January 1985 and 20 December 2024. Only studies published in English or Russian with detailed comprehensive statistics and adult CP were included. Studies with specific patient populations affecting data objectivity were excluded. Sensitivity analyses were conducted (first, only studies with more than 50 CP patients were considered. Second, the analysis was restricted to full articles, excluding abstracts from conferences). Results: In total, 16 studies with 1556 participants (1398 CP patients and 158 controls) met the criteria. The pooled prevalence of sarcopenia was 39.117% (95% CI: 28.891–49.852) in CP patients and 7.745% (95% CI: 2.154–42.622) in the control group. An association was found between sarcopenia and CP using the fixed-effects model when compared to the control group (RR = 2.194, 95% CI: 1.502–3.203). Conclusions: Sarcopenia is underdiagnosed in CP patients despite its significant clinical impact. Management strategies, including pancreatic enzyme replacement therapy, nutritional support, and resistance training show potential in the treatment of this state. Further research is needed to establish standardized diagnostic criteria and unified treatment approaches. Early detection and comprehensive care are essential to improving outcomes in CP patients with sarcopenia.
Objective: This systematic review and meta-analysis aims to evaluate the temporal changes in Helicobacter pylori antibiotic resistance in Russia based on studies published over the past 15 years. Materials and Methods: We conducted a comprehensive literature search in MEDLINE/PubMed, EMBASE, the Russian Science Citation Index, and Google Scholar, following the PRISMA 2020 guidelines. Our meta-analysis was pre-registered in PROSPERO (CRD 420251025636). The inclusion criteria included original research, published in English or Russian in 2011–2024, involving antibiotic susceptibility testing in treatment-naive Russian adults using validated diagnostic methods. Two independent researchers selected studies and extracted data using standardized procedures, with methodological quality assessed via the Newcastle–Ottawa Scale. Pooled resistance rates were calculated using fixed/random-effects models in MedCalc 23.1.5 and Python 3.9.21, with meta-regression investigating temporal trends and subgroup analyses examining regional and methodological variations. Results: We identified 16 studies comprising 1206 H. pylori isolates. The pooled analysis of studies (2011–2025) revealed an overall clarithromycin resistance rate of 15.236%, with a significant temporal increase from 11.903% pre-2015 to 21.024% in 2020–2024 (p = 0.0049). Metronidazole showed consistently high pooled resistance (33.309%), while amoxicillin (1.828%), levofloxacin (19.014%), tetracycline (1.328%), and rifampicin (5.803%) maintained low resistance rates, and dual clarithromycin–metronidazole resistance was observed in 2.793% of isolates. Regional disparities were notable in the two largest cities of Russia, with 18.763% clarithromycin resistance in Moscow versus 28.540% in Saint-Petersburg. Conclusions: Russia surpasses the Maastricht VI Consensus resistance threshold for clarithromycin (15%), necessitating revision of empirical treatment strategies. The significant increase in clarithromycin resistance, potentially exacerbated by antibiotic use during the COVID-19 pandemic, underscores the urgent need for resistance-guided therapies and ongoing national surveillance programs to optimize H. pylori management.
Objective: The objective of this study is to assess the dynamics of Helicobacter pylori infection prevalence among adults in Russia. Methods: A systematic search was conducted in MEDLINE/PubMed, EMBASE, Cochrane, RSCI, and Google Scholar for studies published between 1985 and 27 February 2025, following PRISMA guidelines. The meta-analysis was registered in PROSPERO (CRD420251011643). Results: Twenty studies were included (n = 117,841; weighted mean age: 43.71 ± 16.23 years), all using validated diagnostic methods. The pooled prevalence from 1994 to 2024 was 62.847% (95% CI: 55.101–70.274), including 45.143% (95% CI: 41.390–48.923) by the 13C-urea breath test and 75.806% (95% CI: 64.213–85.742) by serology. Prevalence declined over time: it was 79.334% before 2005, 74.074% in 2006–2011, and 66.319% in 2012–2017, and it has been 42.949% since 2018. Meta-regression confirmed a significant decrease (coefficient: −3.773% per year, p < 0.001). Conclusions: A significant decline in the prevalence of H. pylori has been observed, however, it remains relatively high and requires continued efforts aimed at diagnosis and eradication.
Background/Objectives: Small intestinal bacterial overgrowth (SIBO) is frequently observed in patients treated with proton pump inhibitors (PPIs), yet the role of treatment duration in modulating SIBO risk remains unclear. This meta-analysis aims to evaluate the temporal association between PPI use duration and SIBO risk. Methods: Following the PRISMA 2020 guidelines, a systematic search was conducted across MEDLINE/PubMed, EMBASE, the Cochrane Library, the Russian Science Citation Index, and Google Scholar from 1985 to June 2025 and was previously registered in PROSPERO under the registration number CRD420251031719. Eligible studies included observational designs or clinical trials assessing SIBO in adult PPI users. Results: Twenty-nine studies (n = 3682 PPI patients; n = 2907 controls) were included. The pooled SIBO prevalence among PPI-treated patients was 36.839% (95% CI: 29.703–44.277), significantly higher than that among controls (19.887%; 95% CI: 12.027–29.399). PPI use was associated with increased SIBO risk (OR = 2.143; 95% CI: 1.446–3.175), with high heterogeneity (I2 = 77.61%). A duration-dependent trend was observed: our meta-regression analysis demonstrated a significant positive association between PPI treatment duration and SIBO prevalence with the regression coefficient 4.265% (95% CI: 1.827–6.384; p = 0.0024), indicating that each additional month of PPI therapy was associated with a 4.265 percentage increase in SIBO risk. Conclusions: PPI use significantly increases the risk of SIBO, with longer treatment durations associated with higher odds.
Aim. To systematize data on the trends of the prevalence of Helicobacter pylori infection among the Moscow adult population. Materials and methods. The MEDLINE/PubMed, EMBASE, Google Scholar, and the Russian Science Citation Index were searched for studies published between January 1, 1985, and February 7, 2025, inclusive. Publications were selected based on an analysis of their titles and abstracts. Included were peer-reviewed publications in Russian and English containing data on the prevalence of H. pylori among the adult population of Moscow, studies using validated methods for the diagnosis of H. pylori based on serological, urease respiratory tests, histological and molecular methods, as well as publications containing detailed statistical processing of data suitable for inclusion in the meta-analysis. Results. The final analysis included seven studies totaling 7,581 subjects (the overall mean age of all subjects was 48.28±13.20 years). The overall prevalence of H. pylori infection in the adult population of Moscow in the analyzed pool of studies for 18 years (2006–2024) was 66.534% (95% confidence interval [CI] 42.097–86.989), including 78.661% (95% CI 59.400–92.910) when using serological diagnostic methods and 48.473% (95% CI 32.331–64.781) when using the 13C-urease respiratory test. Studies conducted before 2015 showed the prevalence of H. pylori infection of 81.294% (95% CI 67.202–92.109), 68.028% (95% CI 29.383–95.895) in 2015–2020, and 39.860% (95% CI 33.993–45.877) after 2020. The meta-regression analysis revealed a statistically significant decrease in the prevalence of H. pylori depending on the year of the study (regression coefficient for the year -4.22 (95% confidence interval -6.27–-2.17; p0,0099). Conclusion. The meta-analysis showed a gradual regression in the prevalence of H. pylori infection in Moscow, the largest metropolis in Russia and Europe. However, infection prevalence in the adult population remains relatively high, supporting the need for continued programs of timely diagnosis of H. pylori and subsequent eradication therapy to reduce the risk of associated diseases.
Objective: This umbrella review aimed to synthesize evidence from meta-analyses on the efficacy of rebamipide in major gastrointestinal disorders and dyspeptic symptoms. Methods: This umbrella review followed Joanna Briggs Institute standards and was registered in PROSPERO (CRD420251185686). A comprehensive search of MEDLINE, EMBASE, Cochrane, and Scopus (1 January 1985, to 10 September 2025) was conducted to identify systematic reviews and meta-analyses assessing rebamipide therapy. Methodological quality was appraised using AMSTAR-2, ROBIS, and GRADE tools. Pooled data were analyzed using fixed- or random-effects models according to heterogeneity, as assessed using the I2 statistic. Results: Eleven meta-analyses (88 primary studies) were included. Rebamipide significantly improved H. pylori eradication (OR = 1.76; 95% CI: 1.44–2.16), reduced NSAID-induced mucosal injury (OR = 2.72; 95% CI: 1.89–5.14), enhanced ulcer healing after endoscopic submucosal dissection (OR = 2.28; 95% CI: 1.42–3.65), and alleviated dyspeptic symptoms (OR = 2.95; 95% CI: 1.04–8.37). Overall evidence quality was moderate to high, with low to moderate risk of bias. Conclusions: Rebamipide demonstrates consistent therapeutic benefits across diverse gastrointestinal disorders, improving H. pylori eradication rates, mucosal protection, ulcer healing, and symptom relief. These findings support rebamipide as an effective and well-tolerated adjunctive agent for the prevention and management of upper gastrointestinal diseases.